Macrophage polarity in cancer: A review.


Journal

Journal of cellular biochemistry
ISSN: 1097-4644
Titre abrégé: J Cell Biochem
Pays: United States
ID NLM: 8205768

Informations de publication

Date de publication:
03 2019
Historique:
received: 01 08 2018
accepted: 14 08 2018
pubmed: 3 10 2018
medline: 18 6 2020
entrez: 2 10 2018
Statut: ppublish

Résumé

Macrophages are the most abundant cells within the tumor stroma displaying noticeable plasticity, which allows them to perform several functions within the tumor microenvironment. Tumor-associated macrophages commonly refer to an alternative M2 phenotype, exhibiting anti-inflammatory and pro-tumoral effects. M2 cells are highly versatile and multi-tasking cells that directly influence multiple steps in tumor development, including cancer cell survival, proliferation, stemness, and invasiveness along with angiogenesis and immunosuppression. M2 cells perform these functions through critical interactions with cells related to tumor progression, including Th2 cells, cancer-associated fibroblasts, cancer cells, regulatory T cells (Tregs), and myeloid-derived suppressor cells. M2 cells also have negative cross-talks with tumor suppressor cells, including cytotoxic T cells and natural killer cells. Programed death-1 (PD-1) is one of the key receptors expressed in M2 cells that, upon interaction with its ligand PD-L1, plays cardinal roles for induction of immune evasion in cancer cells. In addition, M2 cells can neutralize the effects of the pro-inflammatory and anti-tumor M1 phenotype. Classically activated M1 cells express high levels of major histocompatibility complex molecules, and the cells are strong killers of cancer cells. Therefore, orchestrating M2 reprogramming toward an M1 phenotype would offer a promising approach for reversing the fate of tumor and promoting cancer regression. Macrophage switching toward an anti-inflammatory M1 phenotype could be used as an adjuvant with other approaches, including radiotherapy and immune checkpoint blockades, such as anti-PD-L1/PD-1 strategies.

Identifiants

pubmed: 30270458
doi: 10.1002/jcb.27646
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

2756-2765

Informations de copyright

© 2018 Wiley Periodicals, Inc.

Auteurs

Masoud Najafi (M)

Department of Radiology and Nuclear Medicine, School of Paramedical Sciences, Kermanshah University of Medical Sciences, Kermanshah, Iran.

Nasser Hashemi Goradel (N)

Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.

Bagher Farhood (B)

Departments of Medical Physics and Radiology, Faculty of Paramedical Sciences, Kashan University of Medical Sciences, Kashan, Iran.

Eniseh Salehi (E)

Department of Anatomy, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

Maryam Shabani Nashtaei (MS)

Department of Anatomy, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Department of Infertility, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.

Neda Khanlarkhani (N)

Department of Anatomy, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

Zahra Khezri (Z)

Department of Anatomy, School of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran.

Jamal Majidpoor (J)

Department of Anatomy, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.

Morteza Abouzaripour (M)

Department of Anatomy, School of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran.

Mohsen Habibi (M)

Department of Radiotherapy, Faculty of Paramedical Science, Tehran University of Medical Sciences, Tehran, Iran.

Iraj Ragerdi Kashani (IR)

Department of Anatomy, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

Keywan Mortezaee (K)

Department of Anatomy, School of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH